Sanofi (NASDAQ:SNY) Sets New 1-Year Low - What's Next?

Key Points

• Sanofi shares hit a new 52-week low of $39.18 and were trading 1.2% lower, below their 50-day and 200-day moving averages.
• Analysts have a consensus “Hold” rating with an average price target of $49.50; coverage includes seven Buy ratings, twelve Holds, one Strong Buy and one Sell.
• Sanofi reported quarterly revenue of $13.36 billion, up 16% year over year, although EPS fell to $2.41 from $3.24; hedge funds and other institutions own 14.03% of the stock.

Sanofi (NASDAQ:SNY - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday. The company traded as low as $39.18 and last traded at $39.2550, with a volume of 2,823,615 shares traded. The stock had previously closed at $39.74.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Sanofi in a research note on Thursday, October 1st. DZ Bank reaffirmed a "buy" rating on shares of Sanofi in a research note on Friday, July 31st. Weiss Ratings raised Sanofi from a "sell (d)" rating to a "sell (d+)" rating in a research note on Thursday. Jefferies Financial Group reiterated a "buy" rating on shares of Sanofi in a report on Thursday, October 1st. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $49.50.

Sanofi Trading Down 1.2%

The firm's 50-day simple moving average is $42.93 and its 200-day simple moving average is $43.95. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $95.22 billion, a PE ratio of 20.56, a price-to-earnings-growth ratio of 1.23 and a beta of 0.33.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The business had revenue of $13.36 billion for the quarter. During the same period last year, the firm earned $3.24 earnings per share. Sanofi's revenue for the quarter was up 16.0% on a year-over-year basis. Equities analysts expect that Sanofi will post 5.00 earnings per share for the current year.

Hedge Funds Weigh In On Sanofi

Several hedge funds have recently made changes to their positions in the business. Manning & Napier Advisors LLC boosted its position in shares of Sanofi by 728,134.8% during the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company's stock valued at $57,542,000 after purchasing an additional 1,194,141 shares in the last quarter. Bank of America Corp DE raised its holdings in Sanofi by 11.0% in the first quarter. Bank of America Corp DE now owns 9,484,350 shares of the company's stock worth $456,956,000 after purchasing an additional 940,342 shares in the last quarter. Regal Partners Ltd raised its holdings in Sanofi by 33.2% in the first quarter. Regal Partners Ltd now owns 2,545,432 shares of the company's stock worth $122,639,000 after purchasing an additional 633,782 shares in the last quarter. Royal Bank of Canada lifted its position in Sanofi by 17.5% during the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company's stock valued at $152,011,000 after buying an additional 470,882 shares during the period. Finally, ADAR1 Capital Management LLC lifted its position in Sanofi by 399.3% during the first quarter. ADAR1 Capital Management LLC now owns 316,939 shares of the company's stock valued at $15,270,000 after buying an additional 253,465 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.